Compare BWEN & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BWEN | RLYB |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 105.5M | 89.2M |
| IPO Year | 2009 | 2021 |
| Metric | BWEN | RLYB |
|---|---|---|
| Price | $3.96 | $16.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 347.6K | 11.5K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 360.00 | N/A |
| EPS | N/A | ★ 6.16 |
| Revenue | ★ $146,785,000.00 | $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.37 | N/A |
| P/E Ratio | ★ N/A | $2.75 |
| Revenue Growth | N/A | ★ 43.00 |
| 52 Week Low | $1.88 | $0.48 |
| 52 Week High | $5.70 | $17.57 |
| Indicator | BWEN | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 39.42 | 59.20 |
| Support Level | $3.46 | $16.51 |
| Resistance Level | $4.15 | $17.32 |
| Average True Range (ATR) | 0.21 | 0.42 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 11.63 | 73.68 |
Broadwind Inc is a precision manufacturer of structures, equipment, and components for clean technology and other specialized applications. The company provides technologically high-value products to customers with complex systems and stringent quality standards that operate in the energy, mining, and infrastructure sectors in the United States of America. Its capabilities include heavy fabrications, welding, metal rolling, coatings, gear cutting and shaping, gearbox manufacturing and repair, heat treatment, CNG decompression, precision machining, assembly, engineering, and packaging solutions, among others. The company operates in four reportable segments: Heavy Fabrications, which generates the maximum revenue, Gearing, Industrial Solutions, and Corporate.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.